Investigational drug · Phase 2
APL-101
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Solid Tumors, Advanced Cancer, Renal Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 27, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "APL-101"
First trial start
2017
Sep 27, 2017
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "APL-101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Tumors
- Advanced Cancer
- Renal Cancer
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- NSCLC
- Lung Cancer
- Brain Tumor
- Glioblastoma Multiforme
- EGFR Gene Mutation
Approved drugs for the same conditions: Non-small cell lung cancer · Stomach and esophageal cancer · Brain tumors (glioma) · Oncology · Kidney and urology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "APL-101" as an intervention, largest first.
Apollomics Inc.Industry
NCT03175224 · 497 participants (planned) · Start Sep 27, 2017 · Primary completion Mar 30, 2026
Drug: APL-101 Oral Capsules · For: Solid Tumors; Advanced Cancer; Renal Cancer and 15 more
Sites: Los Angeles, California; Tampa, Florida; Boston, Massachusetts · 35 sites in all
- A Study Comparing Two Different Capsules, APL-101 and PLB-1001 Capsules, in Healthy Chinese and Caucasian ParticipantsStatus unknown
Apollomics Inc.Industry
NCT05367388 · 48 participants (planned) · Start May 20, 2022 · Primary completion Nov 2022
Drug: APL-101; PLB-1001 · For: Bioequivalence
Sites: Auckland, New Zealand
- Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)Active, not recruiting
Washington University School of MedicineAcademic, hospital or other
NCT04743505 · 27 participants · Start Jan 18, 2022 · Primary completion Jan 31, 2027
Drug: APL-101; Osimertinib · For: Metastatic Non Small Cell Lung Cancer
Sites: St Louis, Missouri
- APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCCTerminated
Apollomics (Australia) Pty. Ltd.Industry
NCT03655613 · 20 participants · Start Sep 5, 2018 · Primary completion Dec 15, 2021
Drug: APL-501; APL-101 and 1 more · For: Hepatocellular Carcinoma; Renal Cell Carcinoma
Sites: Albury, Australia; Sydney, Australia; Westmead, Australia · 9 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Vebreltinib for Advanced Non-Small Cell Lung Cancer Harboring c-Met Exon 14 Skipping Mutation: A Multicenter, Single-Arm, Phase II KUNPENG Study.
Yang JJ, Zhang Y, Wu L, et al. · J Clin Oncol 2024
- Molecular Characterization and Therapeutic Opportunities in KRAS Wildtype Pancreatic Ductal Adenocarcinoma.
Desai A, Xiao AH, Choi D, et al. · Cancers (Basel) 2024
Also in development for Solid Tumors
- 9MW2821Phase 311 trials
Mabwell (Shanghai) Bioscience Co., Ltd. · Urothelial Carcinoma, Advanced Urothelial Carcinoma, Locally Advanced or Metastatic Triple-negative Breast Cancer
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
- AtirmociclibPF-07220060Phase 39 trials
Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- DivarasibGDC-6036, RO7435846Phase 38 trials
Roche (Genentech) · Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer, Non-small Cell Lung Cancer
- HRS-7058Phase 35 trials
Shandong Suncadia Medicine Co., Ltd. · KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment, Solid Tumors, Pancreatic Cancer
- IpatasertibRO5532961, GDC-0068Phase 35 trials
Roche (Genentech) · Metastatic Breast Cancer, Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer, Ovarian Cancer
- DB-1311BNT324Phase 34 trials
BioNTech SE · Metastatic Castration-resistant Prostate Cancer, Advanced Lung Cancer, Solid Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.